Magazine Article | May 3, 2021

Companies To Watch: Lyra Therapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Controlling chronic ENT conditions with precise drug elution and long action

SNAPSHOT

Lyra Therapeutics is a developer of therapies aimed at specific causes of ear, nose, and throat diseases. The treatments are drugs assisted by extended-release devices. Its two lead products in the development pipeline target chronic rhinosinusitis (CRS), a debilitating nasal inflammatory disease typically affecting millions of patients throughout their lifetimes, under different circumstances. One, coded LYR-210, is a long-acting anti-inflammatory (mometasone furoate) implanted in surgery-naïve patients, now in preparation for a Phase 3 trial. The other, LYR- 220, now completing preclinical development, delivers the same drug but with a device designed for post-surgery patients. Both products are based on the company’s XTreo platform, similar to drug-eluting stent technology combining a biocompatible mesh scaffold, engineered elastomeric matrix, and a polymer-drug complex.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: